Skip to content
naulon
Not checkedNot checked for notices yet.

Comparison of pain on injection of newer formulation propofol and standard propofol with added lignocaine: A randomised double-blind prospective study

Settipalli Suneela, Radhapuram Sri Devi, Mangu Hanumantha Rao and 1 more

Journal of Clinical and Scientific Research · 2020

doi:10.4103/jcsr.jcsr_17_19 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Background: The aim of the present prospective randomised double-blind clinical study was to compare the incidence of pain-free injection following the use of this new formulation (propofol with medium-chain triglycerides [MCT] and long-chain triglycerides [LCT]) with propofol dissolved in LCT with added 2% lignocaine in patients undergoing various surgical procedures under general anaesthesia. Methods: Sixty adult patients (age range 18–50 years) were randomised to receive either 20 mL propofol dissolved in a mixture of MCT–LCT [Group L (n = 30)] or 18 mL propofol dissolved in LCT with added 2 mL 2% lignocaine [Group S (n = 30)]. A specially trained clinical research investigator assessed the occurrence of injection pain using a four-graded pain scale. Results: There was no significant difference in propofol injection pain among patients who received either LCT propofol with added lidocaine, (Group S) (33.3%) or new formulation propofol (Group L) (30.0%) (P = 0.993). Conclusions: The newer formulation, MCT–LCT propofol, is equally effective vis-à-vis the conventional propofol with added lignocaine to reduce the incidence of pain, thereby eliminating the need for addition of another drug, lignocaine.

Abstract licence: CC BY-NC-SA

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.